Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Attendees

 

Attended

Name

Affiliation

1

Cary Paul

Pivotal Insight, LLC.

2

x

David Crooke

Pivotal Insight, LLC.

23

Amy Stowers

Maximus

34

x

Ken Rubin

VA/Utah

45

x

Linda Chan

Pivotal Insight, LLC.

56

x

Dhruv Sharma

ACEP

67

x

John Svirbely

Trisotech

78

x

Shane McNamee

Perspecta

89

Tracie Berardi

OMG

10

9x

Pawan Goyal

ACEP10

11

x

Mike Cesino

 Visible Systems Corporation

12

x

Mike Meier

Agenda and Minutes

...

Agenda Item

  • Authoring Clinical Steering Committee on Thursday, July 9, 12:00PM – 1:00pm EST

  • Workgroup on Monday, June,

    Meeting Notes

    Thank you all!

    Next Mtgs:

    View file
    name2020-21 Work PRoduct B rainstorming .pptx

    Business Use Case Analysis

    • Who are the buyers

    • What is the price

    • Business Trends

    • ROI

    • Spans the communities and holistic around all of BPM+

    Statement of Value

    • What is the benefits

    • What are the key value statements for different action and communications

    • Target Audience: Arriving toward and organization that wants to do authoring of clinical pathways

    • Differentiate between those that want to do authoring verse those that are trying to consume authored artifacts

    Out of Scope of Authoring Work group

    • Why an institution would want to adopt or institute shareable pathways

    • Bill: Are there studies about how pathways are instituted and used, and the implications of that. (ref: Look at oncology Pathways)

    Examples:

    Clinical Pathways: Reducing Costs and Improving Quality Across a Network

    Impact of Electronically Accessible Pathways on Clinical Trial Enrollment at a Large Multisite Cancer Center

    Work What Success looks like? (6-12 mos)

    • Why would someone want to be involved

    • What is the path-How do I start, and what does the path look like?

    • Best practices-how do I do this well ? What has been learned? What guidance should I follow?

    • Why should I want to be an author involved in BPM+?

    • “How does one take a 100+page PDF guideline and make it into a machine readable model that could be ingested into a system.” Taking the story, approach, tips, tricks, etc. so that other can do this. Either de novo or adapting existing content. This is authoring.

      • New clinical societies

      • Healthcare delivery orgs

      • Etc.

    • Why would an organization choose this ?

    • If we make the decision, how do we make it so?

    • What does “doing it well” looks like: (e.g. Maturity Model, etc.)

    Sample: The Product Vision Board

    Work Products to do this

    • Artifact: Criteria Set/Guide ( ?)

      • Purpose: Define what a well authored model looks like

      • Audience: Person or org stepping up and establishing an authoring capability

        • As a Technologies: Defines what a well authored model looks like

        • As a Functional: Shows what a well authored model looks like

        • Business: secondary reference

      • Contents:

        • Investments that would need to be made (e.g Tooling, training

        • How to address variability and drive towards consistency (e.g., glossaries, patterns, standardized nomenclature, terminology) ; recognize and applying patterns

        • Snapshot of good authoring practices, approaches. Best practices, characteristics, etc. Potential maturity model to advance organizational capacity to develop pathways.

        • Quality criteria-what represents a good authored artifacts.

        • Dealing with settings, variances, local adaptation/configuration

        • Access to functional expertise

    Work Products to do this

    What is the artifact: Value Proposition for Authoring Organizations

    • What is the purpose

      • Explain why formal authoring is valuable

      • Helping advance usability of EHRs: role in improving efficacy of EHR

      • Marrying CPGs into clinical practice congruent to clinical workflow;

      • Making these more consumable and implementable

    • Who is its audience:

      • As a Technologies: Clinical embeds supporting technology companies

      • As a Functional: Full spectrum clinical community, those building guidelines or maintaining them;

      • Business: secondary reference

      • Adopting organization: rationalize the art of the possible; value of direct consumption of guidelines.

      • Specialty Societies: Authoritative creators or stewards of content.

      • Payers:

    • Contents:

      • Mission

      • Specific Purpose

      • “Customers”

      • Problem being solved

      • Unique value proposition

      • Case Studies/Exemplars

    Action items:

    • Review and integrate business case outline with the new artifacts

    • Linda Chan to set up 2 sub meetings

      • Value Prop-Shane McNamee, Mike Cesino, Pawan Goyal

      • Criteria-Mike Meir/John Svirbely

    Next Mtgs:

    • Workgroup on Monday, July 20 2:30pm – 4pm EST

    • Authoring Clinical Steering Committee on Thursday, July 23,

    ...

    • 12:00PM – 1:00pm EST

    • Workgroup on Monday, August

    ...

    • 3 2:30pm – 4pm EST

    • Authoring Clinical Steering Committee on Thursday, Aug 23, 12:00PM – 1:00pm EST